首页 › 基金 › Propel Bio Management, LLC › PHAT
Propel Bio Management, LLC 对 PHAT 的持仓历史
PHATHOM PHARMACEUTICALS INC · 医疗保健
Propel Bio Management, LLC 在 Q3 2026 的 13F 申报中披露持有 PHAT(PHATHOM PHARMACEUTICALS INC)1,105,913 股,市值约 US$8.1M,约占其申报组合的 4.28%,在其申报持仓中市值排名第 8 位。 Propel Bio Management, LLC 最近 12 个申报季度中有 12 个季度披露了 PHAT 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Propel Bio Management, LLC 对 PHAT 的持仓演变
Propel Bio Management, LLC 于 Q4 2023 首次披露 PHAT 持仓:443,047 股(约 US$4.0M)。 该持仓在 Q3 2024 达到峰值 869,927 股,市值约 US$15.7M。 在 12 次申报中,Propel Bio Management, LLC 7 次增持、2 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 1,105,913 股、市值约 US$8.1M,环比增持 55,555 股。。 持仓曾出现大幅变动:Q1 2024 增持约 96% (随后一个季度股价下跌 3%)、Q3 2025 减持约 40% (随后一个季度股价上涨 41%)、Q4 2025 增持约 34% (随后一个季度股价下跌 33%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 443.05K | $4.05M | 新进 |
| Q1 2024 | 869.93K | $9.24M | 增持 |
| Q2 2024 | 869.93K | $8.96M | 持有 |
| Q3 2024 | 869.93K | $15.73M | 持有 |
| Q4 2024 | 989.93K | $8.04M | 增持 |
| Q1 2025 | 1.13M | $7.12M | 增持 |
| Q2 2025 | 922.93K | $8.85M | 减持 |
| Q3 2025 | 552.93K | $6.51M | 减持 |
| Q4 2025 | 740.92K | $12.29M | 增持 |
| Q1 2026 | 841.27K | $9.35M | 增持 |
| Q2 2026 | 1.05M | $11.40M | 增持 |
| Q3 2026 | 1.11M | $8.07M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PHAT 与 13F 数据
PHAT(PHATHOM PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 29 只申报持有 PHAT,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), Carlyle Group Inc. (US$25.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PHAT 的基金
- Frazier Life Sciences Management, L.P. 12.47M 股 · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M 股 · $54.49M · Q3 2026
- Carlyle Group Inc. 3.50M 股 · $25.53M · Q3 2026
- NEA Management Company, LLC 1.96M 股 · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M 股 · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M 股 · $13.74M · Q3 2026
- EcoR1 Capital, LLC 625.00K 股 · $6.78M · Q2 2026
更多关于 Propel Bio Management, LLC
常见问题
How long has Propel Bio Management, LLC held PHAT?
Propel Bio Management, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Propel Bio Management, LLC's current position in PHAT?
As of Q3 2026, Propel Bio Management, LLC holds 1.11M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $8.07M, representing 4.28% of its reported portfolio and ranking #8.
Has Propel Bio Management, LLC been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in PHAT. The position peaked in Q3 2024 at 869.93K shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.